Editorial: Advancements in immunology and immunotherapy for breast cancer.

Competing Interests: TS reports research funding from Chugai/Roche, Eisai and Kyoto Bridge for Breakthrough Medicine, honoraria from Chugai/Roche, Merck Sharp & Dohme (MSD), Astra Zeneca, Pfizer, Eli Lilly, Taiho, Daiichi Sankyo and Eisai. RS reports non-financial support from MSD and Bristol Myers Squibb (BMS), research support from MSD, Puma Biotechnology and Roche, and personal fees from Roche, BMS and Exact Sciences for advisory boards. LF reports research funding to the institution from Abbvie, Amgen, Bavarian Nordic, BMS, Dendreon, Janssen, MSD, and Roche/Genentech. LF reports consulting or advisory role with BMS, Daiichi Sankyo, Innovent, MSD, Roche/Genentech, and EMD Serono.